Drug intelligence / Profile preview

GEn-1123

Development stage: Preclinical
Lead developer: Gen1E Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

GEn-1123 is an orally administered small molecule dual signal modulator developed by Gen1E Lifesciences. It is designed to target the p38α (mitogen-activated protein kinase 14) and MK2 (MAP kinase-activated protein kinase 2) signaling pathway, which is a critical regulator of pro-inflammatory cytokine production. By employing a dual modulation approach, GEn-1123 aims to achieve potent anti-inflammatory effects while potentially mitigating the toxicity and off-target issues historically associated with traditional p38 kinase inhibitors. The drug is currently being developed for the treatment of rare chronic inflammatory diseases.

Other names: GEn-1123GEn1123GEn 1123

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)MK2 (Mitogen-activated protein kinase-activated protein kinase 2)

Beyond the preview

Go deeper on GEn-1123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEn-1123.

Explore the full profile